ANI Pharmaceuticals (ANIP) said Tuesday that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding on global net revenue of Iluvien and Yutiq for a one-time payment of $17.3 million.
The company said it financed the buyout with cash on hand, and that no additional royalty is due to SWK on net revenue beginning Jan. 1 of this year and forward.
Shares of the company were down more than 1% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.